Asuragen
在场
Asuragen 的所有者是 Bio-Techne.
是其中之一......
Bio-Techne 是一家在股票代码 TECH (US) 下上市的公司。
他们在：
涉及Bio-Techne的并购和融资。
- Bio-Techne has announced the acquisition of Lunaphore (公布2023六月23号).
高管
查看带有其 8 名主要高管的组织结构图
Asuragen 搜索最多的简介
- Matt Winkler, Chairman of the Board and Chief Scientific Officer
- David Sargent, Director
- Deval Lashkari, Director
高管在Bio-Techne变化
- Judith Klimovsky已作为Director加入公司 (新闻发布的2024五月2号).
创建提醒
跟踪 Asuragen 的高管变动
生物技术
Bio-Techne 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Asuragen 的最新新闻稿
- https://twitter.com/home?status=Bio-Techne%20Launches%20%3Cem%3E%20ESR1%20%3C%2Fem%3E%20Mutation%20Monitoring%20Assay%20https%3A%2F%2Fasuragen.com%2Fnews-list%2Fbio-techne-launches-esr1-mutation-monitoring-assay%2F
- LinkedIn Login, Sign in | LinkedIn
- Log in or sign up to view
- Bio-Techne Launches ESR1 Mutation Monitoring Assay - Asuragen
- LinkedIn Login, Sign in | LinkedIn
- Bio-Techne to highlight novel solutions for cancer and carrier screening at AMP 2024 Annual Meeting & Expo - Asuragen
- Log in or sign up to view
- X. It’s what’s happening
- https://twitter.com/home?status=Bio-Techne%20Receives%20European%20IVDR%20Certification%20for%20Diagnostic%20Test%20To%20Monitor%20Chronic%20Myeloid%20Leukemia%20https%3A%2F%2Fasuragen.com%2Fnews-list%2Fbio-techne-receives-european-ivdr-certification-for-diagnostic-test-to-monitor-chronic-myeloid-leukemia%2F
- LinkedIn Login, Sign in | LinkedIn
- View more press releases Close
通过电子邮件
